Part 3.9 / M31, M34

Catalogusnummer

►M18  Chemische naam ◄

EG-nr.

CAS-nr.

Indeling

Etikettering

►M18  Specifieke concentratiegrenzen, M-factoren en ATE's (*1)  ◄

Opmerkingen

Gevarenklasse en

-categorie

Gevarenaanduiding

Pictogram, signaalwoord

Gevarenaanduiding

Aanvullende gevarenaanduiding

▼M16

005-007-00-2

boorzuur; [1]

boorzuur [2]

233-139-2 [1]

234-343-4 [2]

10043-35-3 [1]

11113-50-1 [2]

Repr. 1B

H360FD

GHS08

Dgr

H360FD

11

005-008-00-8

diboortrioxide

215-125-8

1303-86-2

Repr. 1B

H360FD

GHS08

Dgr

H360FD

11

005-011-00-4

tetraboordinatriumheptaoxide, hydraat; [1]

dinatriumtetraboraat, watervrij; [2]

orthoboorzuur, natriumzout; [3]

dinatriumtetraboraat-decahydraat; [4]

dinatriumtetraboraat-pentahydraat [5]

235-541-3 [1]

215-540-4 [2]

237-560-2 [3]

215-540-4 [4]

215-540-4 [5]

12267-73-1 [1]

1330-43-4 [2]

13840-56-7 [3]

1303-96-4 [4]

12179-04-3 [5]

Repr. 1B

H360FD

GHS08

Dgr

H360FD

11

014-001-00-9

trichloorsilaan

233-042-5

10025-78-2

Flam. Liq. 1

Water-react. 1

Acute Tox. 3

Acute Tox. 4

Skin Corr. 1A

Eye Dam. 1

H224

H260

H331

H302

H314

H318

GHS02

GHS06

GHS05

Dgr

H224

H260

H331

H302

H314

EUH014

EUH029

EUH071

inademing:

ATE = 7,6 mg/l (dampen)

oraal:

ATE = 1 000 mg/kg lg

014-052-00-7

silaanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolyseproducten met silica; pyrogeen, synthetisch amorf, nano siliciumdioxide met behandeld oppervlak

272-697-1

68909-20-6

STOT RE 2

H373 (longen) (inademing)

GHS08

Wng

H373 (longen) (inademing)

EUH066

023-001-00-8

divanadiumpentaoxide; vanadiumpentaoxide

215-239-8

1314-62-1

Muta. 2

Carc. 1B

Repr. 2

Lact.

Acute Tox. 3

Acute Tox. 2

STOT SE 3

STOT RE 1

Aquatic Chronic 2

H341

H350

H361fd

H362

H301

H330

H335

H372 (ademhalingswegen, inademing)

H411

GHS06

GHS08

GHS09

Dgr

H341

H350

H361fd

H362

H301

H330

H335

H372 (ademhalingswegen, inademing)

H411

inademing:

ATE = 0,05 mg/L (stofdeeltjes of nevels)

oraal:

ATE = 220 mg/kg lg

035-005-00-7

ammoniumbromide

235-183-8

12124-97-9

Repr. 1B

Lact.

STOT SE 3

STOT RE 1

Eye Irrit. 2

H360FD

H362

H336

H372 (zenuwstelsel)

H319

GHS08

GHS07

Dgr

H360FD

H362

H336

H372 (zenuwstelsel)

H319

050-032-00-4

dibutyltinbis(2-ethylhexanoaat)

220-481-2

2781-10-4

Muta. 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immuunsysteem)

GHS08

Dgr

H341

H360FD

H372 (immuunsysteem)

050-033-00-X

dibutyltindi(acetaat)

213-928-8

1067-33-0

Muta. 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immuunsysteem)

GHS08

Dgr

H341

H360FD

H372 (immuunsysteem)

052-001-00-0

telluur

236-813-4

13494-80-9

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362

052-002-00-6

telluurdioxide

231-193-1

7446-07-3

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362

056-005-00-3

bariumdiboortetraoxide

237-222-4

13701-59-2

Repr. 1B

Acute Tox. 4

Acute Tox. 3

H360FD

H332

H301

GHS08

GHS06

Dgr

H360FD

H332

H301

inademing:

ATE = 1,5 mg/L (stofdeeltjes of nevels)

oraal:

ATE = 100 mg/kg lg

601-024-00-X

cumeen

202-704-5

98-82-8

Flam. Liq. 3

Carc. 1B

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H350

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H350

H304

H335

H411

601-097-00-8

propylbenzeen

203-132-9

103-65-1

Flam. Liq. 3

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H304

H335

H411

603-014-00-0

2-butoxyethanol; ethyleenglycolmonobutylether

203-905-0

111-76-2

Acute Tox. 3

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

H331

H302

H315

H319

GHS06

Dgr

H331

H302

H315

H319

inademing:

ATE = 3 mg/l (dampen)

oraal:

ATE = 1 200 mg/kg lg

603-107-00-6

2-(2-methoxyethoxy)ethanol; diëthyleenglycolmonomethylether

203-906-6

111-77-3

Repr. 1B

H360D

GHS08

Dgr

H360D

Repr. 1B; H360D: C ≥ 3 %

603-243-00-6

2,2-dimethylpropaan-1-ol, tribroomderivaat; 3-broom-2,2-bis(broommethyl)propaan-1-ol

253-057-0

36483-57-5; 1522-92-5

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341

604-030-00-0

4,4'-isopropylideendifenol; bisfenol A

201-245-8

80-05-7

Repr. 1B

STOT SE 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360F

H335

H318

H317

H400

H410

GHS08

GHS07

GHS05

GHS09

Dgr

H360F

H335

H318

H317

H410

M = 1

M = 10

604-096-00-0

piperonylbutoxide (ISO); 2-(2-butoxyethoxy)ethyl-6-propylpiperonylether

200-076-7

51-03-6

STOT SE 3

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H335

H319

H400

H410

GHS07

GHS09

Wng

H335

H319

H410

EUH066

M = 1

M = 1

604-097-00-6

2,4,6-tri-tert-butylfenol

211-989-5

732-26-3

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1B

H360D

H302

H373 (lever)

H317

GHS08

GHS07

Dgr

H360D

H302

H373 (lever)

H317

oraal:

ATE = 500 mg/kg lg

604-098-00-1

4,4'-sulfonyldifenol; bisfenol S

201-250-5

80-09-1

Repr. 1B

H360FD

GHS08

Dgr

H360FD

606-153-00-5

benzofenon

204-337-6

119-61-9

Carc. 1B

H350

GHS08

Dgr

H350

606-154-00-0

quinoclamin (ISO); 2-amino-3-chloor-1,4-naftochinon

220-529-2

2797-51-5

Carc. 2

Repr. 2

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H302

H373 (bloedstelsel, nieren)

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H302

H373 (bloedstelsel, nieren)

H319

H317

H410

oraal:

ATE = 500 mg/kg lg

M = 10

M = 10

607-111-00-9

2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propaandiyldiacrylaat; 2,2-bis(acryloyloxymethyl)butylacrylaat;

trimethylolpropaantriacrylaat

239-701-3

15625-89-5

Carc. 2

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H315

H319

H317

H410

M = 1

M = 1

D

607-230-00-6

2-ethylhexaanzuur en zouten daarvan, tenzij elders in deze bijlage vermeld

—

—

Repr. 1B

H360D

GHS08

Dgr

H360D

A, X, 12

607-253-00-1

cyfluthrin (ISO); α-cyaan-4-fluor-3-fenoxybenzyl-3-(2,2-dichloorvinyl)-2,2-dimethylcyclopropaancarboxylaat

269-855-7

68359-37-5

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (zenuwstelsel)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (zenuwstelsel)

H410

inademing:

ATE = 0,14 mg/L (stofdeeltjes of nevels)

oraal:

ATE = 14 mg/kg lg

M = 1 000 000

M = 1 000 000

607-254-00-7

bèta-cyfluthrin (ISO); reactiemassa van: rel-(R)-cyaan(4-fluor-3-fenoxyfenyl)methyl (1S,3S)-3-(2,2-dichloorethenyl)-2,2-dimethylcyclopropaan-1-carboxylaat en rel-(R)-cyaan(4-fluor-3-fenoxyfenyl)methyl (1S,3R)-3-(2,2-dichloorethenyl)-2,2-dimethylcyclopropaan-1-carboxylaat

—

1820573-27-0

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (zenuwstelsel)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (zenuwstelsel)

H410

inademing:

ATE = 0,081 mg/L (stofdeeltjes of nevels)

oraal:

ATE = 11 mg/kg lg

M = 1 000 000

M = 1 000 000

607-734-00-6

pentakalium 2,2”,2”,2"’,2""-(ethaan-1,2-diylnitrilo)penta-acetaat

404-290-3

7216-95-7

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inademing)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inademing)

H319

Repr. 1B; H360D: C ≥ 3 %

inademing:

ATE = 1,5 mg/L (stofdeeltjes of nevels)

607-735-00-1

N-carboxymethyliminobis(ethyleennitrilo)tetraazijnzuur

200-652-8

67-43-6

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inademing)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inademing)

H319

Repr. 1B; H360D: C ≥ 3 %

inademing:

ATE = 1,5 mg/L (stofdeeltjes of nevels)

607-736-00-7

pentanatrium(carboxylatomethyl)iminobis(ethyleennitrilo)tetraäcetaat

205-391-3

140-01-2

Repr. 1B

Acute Tox. 4

STOT RE 2

H360D

H332

H373 (inademing)

GHS08

GHS07

Dgr

H360D

H332

H373 (inademing)

Repr. 1B; H360D: C ≥ 3 %

inademing:

ATE = 1,5 mg/L (stofdeeltjes of nevels)

607-756-00-6

exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylacrylaat; isobornylacrylaat

227-561-6

5888-33-5

Skin Sens. 1A

H317

GHS07

Wng

H317

607-757-00-1

daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutaanzuur; N-dimethylaminosuccinamidezuur

216-485-9

1596-84-5

Carc. 2

H351

GHS08

Wng

H351

607-758-00-7

4,4'-oxydi(benzeensulfonohydrazide)

201-286-1

80-51-3

Self-react. D

Aquatic Acute 1

Aquatic Chronic 1

H242

H400

H410

GHS02

GHS09

Dgr

H242

H410

M = 1

M = 1

607-759-00-2

tolueen-4-sulfonohydrazide

216-407-3

1576-35-8

Self-react. D

H242

GHS02

Dgr

H242

607-760-00-8

2-[N-ethyl-4-[(5-nitrothiazool-2-yl)azo]-m-toluïdino]-ethylacetaat; C.I. Disperse Blue 124

239-203-6

15141-18-1

Skin Sens. 1A

H317

GHS07

Wng

H317

Skin Sens. 1A; H317: C ≥ 0,001 %

607-761-00-3

perfluorheptaanzuur; tridecafluorheptaanzuur

206-798-9

375-85-9

Repr. 1B

STOT RE 1

H360D

H372 (lever)

GHS08

Dgr

H360D

H372 (lever)

607-762-00-9

methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chloorfenyl)-β-alaninaat; valifenalaat

—

283159-90-0

Carc. 2

Aquatic Chronic 2

H351

H411

GHS08

GHS09

Wng

H351

H411

607-763-00-4

6-[C12-18-alkyl-(vertakt, onverzadigd)-2,5-dioxopyrrolidine-1-yl]hexaanzuur, natrium en tris(2-hydroxyethyl)-ammoniumzouten

—

—

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319

607-764-00-X

6-[(C10-C13)-alkyl-(vertakt, onverzadigd)-2,5-dioxopyrrolidine-1-yl]hexaanzuur

—

2156592-54-8

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319

607-765-00-5

6-[C12-18-alkyl-(vertakt, onverzadigd)-2,5-dioxopyrrolidine-1-yl]hexaanzuur

—

—

Repr. 1B

H360FD

GHS08

Dgr

H360FD

608-032-00-2

acetamiprid (ISO); (1E)-N-[(6-chloorpyridine-3-yl)methyl]-N'-cyaan-N-methylethanimidamide; (E)-N1-[(6-chloor-3-pyridyl)methyl]-N2-cyaan-N1-methylacetamidine

—

135410-20-7 160430-64-8

Repr. 2

Acute Tox. 3

Aquatic Chronic 1

Aquatic Acute 1

H361d

H301

H410

H400

GHS08

GHS06

GHS09

Dgr

H361d

H301

H410

oraal:

ATE = 140 mg/kg lg

M = 10

M = 10

609-042-00-X

pendimethaline (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylideen

254-938-2

40487-42-1

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GSH09

Wng

H361d

H410

M = 100

M = 10

613-012-00-1

bentazon (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-on-2,2-dioxide

246-585-8

25057-89-0

Repr. 2

Acute Tox. 4

Eye Irrit. 2

Skin Sens. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

oraal: ATE = 1 600 mg/kg lg

613-341-00-0

clofentezine (ISO); 3,6-bis(o-chloorfenyl)-1,2,4,5-tetrazine

277-728-2

74115-24-5

Aquatic Chronic 1

H410

GHS09

Wng

H410

M = 1

613-342-00-6

theofylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dion

200-385-7

58-55-9

Repr. 1B

H360D

GHS08

Dgr

H360D

613-343-00-1

pyridalyl (ISO); 2,6-dichloor-4-(3,3-dichloorallyloxy)-fenyl 3-[5-(trifluormethyl)-2-pyridyloxy]propylether

—

179101-81-6

Skin Sens. 1

Aquatic Acute

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1 000

M = 100

613-344-00-7

pyridine-2-thiol-1-oxide, natriumzout; pyrithionnatrium; natriumpyrithion

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT RE 1

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 2

H331

H311

H302

H372 (zenuwstelsel)

H315

H319

H317

H400

H411

GHS06

GHS08

GHS09

Dgr

H331

H311

H302

H372 (zenuwstelsel)

H315

H319

H317

H410

EUH070

inademing:

ATE = 0,5 mg/L (stofdeeltjes of nevels)

dermaal:

ATE = 790 mg/kg lg

oraal:

ATE = 500 mg/kg lg

M = 100

613-345-00-2

1,3,5-triazine-2,4,6-triamine;

melamine

203-615-4

108-78-1

Carc. 2

STOT RE 2

H351

H373 (urinewegen)

GHS08

Wng

H351

H373 (urinewegen)

615-046-00-2

1,3-bis(1-isocyanato-1-methylethyl)benzeen; [m-TMXDI]

220-474-4

2778-42-9

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317

615-047-00-8

1,3-bis(isocyanatomethyl)benzeen; [m-XDI]

222-852-4

3634-83-1

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317

Skin Sens. 1A; H317: C ≥ 0,001 %

615-048-00-3

2,4,6-triisopropyl-m-fenyleendiisocyanaat

218-485-4

2162-73-4

Resp. Sens. 1

Skin Sens. 1

H334

H317

GHS08

Dgr

H334

H317

615-049-00-9

1,5-naftyleendiisocyanaat

[met < 0,1 % (m/m) deeltjes met een aerodynamische diameter van minder dan 50 μm]

221-641-4

3173-72-6

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412

615-050-00-4

1,5-naftyleendiisocyanaat

[met ≥ 0,1 % (m/m) deeltjes met een aerodynamische diameter van minder dan 50 μm]

221-641-4

3173-72-6

Acute Tox. 2

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H330

H335

H315

H319

H334

H317

H412

GHS06

GHS08

Dgr

H330

H335

H315

H319

H334

H317

H412

inademing:

ATE = 0,27 mg/L (stofdeeltjes of nevels)

616-164-00-7

dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylfenoxy)methyl]fenyl}-2-(methoxyimino)-N-methylaceetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]aceetamide

149961-52-4

Carc. 2

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H332

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H332

H410

inademing:

ATE = 1,3 mg/L (stofdeeltjes of nevels)

M = 100

M = 100

616-237-00-3

fluopicolide (ISO); 2,6-dichloor-N-[3-chloor-5-(trifluormethyl)-2-pyridylmethyl]benzamide

—

239110-15-7

Repr. 2

H361d

GHS08

Wng

H361d

616-238-00-9

N-(2-nitrofenyl)fosforzuurtriamide

477-690-9

874819-71-3

Repr. 1B

STOT RE 2

H360Fd

H373 (nieren)

GHS08

Dgr

H360Fd

H373 (nieren)

616-239-00-4

N-(5-chloor-2-isopropylbenzyl)-N-cyclopropyl-3-(difluormethyl)-5-fluor-1-methyl-1H-pyrazool-4-carboxamide; isoflucypram

—

1255734-28-1

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H361f

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361f

H332

H317

H410

inademing:

ATE = 2,2 mg/L (stofdeeltjes of nevels)

M = 10

M = 1

616-240-00-X

reactiemassa van 3-(difluormethyl)-1-methyl-N-[(1RS, 4SR, 9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaftaleen-5-yl]pyrazool-4-carboxamide en 3-(difluormethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaftaleen-5-yl]pyrazool-4-carboxamide [≥ 78 % syn-isomeer ≤ 15 % anti-isomeer relatief gehalte] isopyrazam

—

881685-58-1

Carc. 2

Repr. 1B

Skin Sens. 1B

Aquatic Acute 1 Aquatic Chronic 1

H351

H360D

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H317

H410

Repr. 1B; H360D:

C ≥ 3 %

M = 10

M = 10

650-058-00-1

margosa-extract [van het zaad van Azadirachta indica, geëxtraheerd met water en verder behandeld met organische oplosmiddelen]

283-644-7

84696-25-3

Repr. 2

Skin Sens. 1

Aquatic Chronic 1

H361d

H317

H410

GHS08

GHS07

GHS09

Wng

H361d

H317

H410

M = 10

▼B